We also have clinical data from R/R B-ALL patients treated in clinical trials with other CAR-T cells not approved for clinical use, with anti-CD19 specificity and anti-B markers such as CD22, co-stimulated by 4-1BB or CD28. Here, CD22 is linked to acute lymphoblastic leukemia.